A METHOD FOR PREPARING THERAPEUTIC FORMULATION DERIVED FROM ATROPA BELLADONNA TO IMPEDE DPP4

Abstract

ABSTRACT A method (100) for preparing therapeutic formulation derived from Atropa belladonna to impede DPP4. The method (100) comprising extracting active compounds from Atropa belladonna using a suitable solvent selected from the group consisting of ethanol, methanol, and aqueous solutions, at a temperature ranging from 25°C to 60°C, for a duration of 2 to 24 hours. Further, filtering the extract to remove solid residues and obtaining a clear liquid extract containing the active phytochemicals. Further, concentrating the filtered extract under reduced pressure at a temperature not exceeding 40°C to obtain a concentrated extract. Further, mixing the concentrated extract with pharmaceutically acceptable excipient. Further, characterizing the therapeutic formulation for DPP4 inhibitory activity using computational approach (i.e. Molecular docking).

Specification

Description:
FIELD OF THE DISCLOSURE
[0001] This invention generally relates to a field of therapeutic formulation and, in particular to a method for for preparing therapeutic formulation derived from Atropa belladonna to impede DPP4.
BACKGROUND

[0002] The subject matter discussed in the background section should not be assumed to be prior art merely as a result of its mention in the background section. Similarly, a problem mentioned in the background section or associated with the subject matter of the background section should not be assumed to have been previously recognized in the prior art. The subject matter in the background section merely represents different approaches, which in and of themselves may also correspond to implementations of the claimed technology.
[0003] The novel therapeutic agents derived from natural sources has intensified in recent years, particularly due to the rising prevalence of metabolic disorders such as diabetes. Atropa belladonna, a plant known for its rich array of alkaloids, has , Claims:1. A method (100) for preparing therapeutic formulation derived from Atropa belladonna to impede DPP4, the method comprising:
extracting active compounds from Atropa belladonna using a suitable solvent selected from the group consisting of ethanol, methanol, and aqueous solutions, at a temperature ranging from 25°C to 60°C, for a duration of 2 to 24 hours, at step 102;
filtering the extract to remove solid residues and obtaining a clear liquid extract containing the active phytochemicals, at step 104;
concentrating the filtered extract under reduced pressure at a temperature not exceeding 40°C to obtain a concentrated extract, at step 106;
mixing the concentrated extract with pharmaceutically acceptable excipient, at step 108; and
characterizing the therapeutic formulation for DPP4 inhibitory activity using computational approach (i.e. Molecular docking), at step 110.

2. The method (100) as claimed in claim 1, wherein the pharmaceutically acceptable excipient comprises binders, fillers, disintegrants, an

Documents